; and (II) the date that is 1 year after the date on which the generic drug that is the subject of the abbreviated new drug application described in subclause (I) enters the marketplace; or (B) with respect to a reference product, the period between— (i) the date that is the earlier of— (I) 6 years before any patent or marketing exclusivity (including any extension of such exclusivity) granted under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) or section 527 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360cc ) with respect to such reference product expires; and (II) the date on which the first biosimilar biological product license application that references such reference product is filed; and (ii) the later of— (I) the date that is 180 days after the date on which the first biosimilar biological product license application that references such reference product enters the marketplace; and (II) the date that is 1 year after the date on which the biosimilar biological product that is the subject of the biosimilar biological product license application described in subclause (I) enters the marketplace. (5) Expected revenue The term expected revenue , with respect to a follow-on product, means the financial value represented by the number of individuals in the target population multiplied by the financial revenue generated by each member of the target population over the 3-year period beginning— (A) on the day that 3 generic drugs referencing the same listed drug or 2 or more biosimilar biological products referencing the same reference product would have been widely available in the market